Table 3.

Participants experiencing treatment related adverse events; N = 64

Adverse eventsDHAPlacebo
(Grade 1–2)aN = 32N = 32
GI Disorders
 NOS27
 Flatulence23
 Diarrhea12
 Dysgeusia21
 Nausea02
 Dyspepsia20
 Abdominal pain01
 Bloating01
 GERD01
Breast pain11
Anemia10
Arthralgia01
Headache11
Hot flashes10
Weight gain01
  • Abbreviations: GERD, gastroesophageal reflux disease; NOS, not otherwise specified.

  • aThere were no ≥ grade 3 adverse events related to study drug.